Correlation of features of Allergic rhinitis and Allergic conjunctivitis with Treatment Modalities

Abstract

Introduction:

Allergic Rhinitis (AR) is a chronic, symptomatic allergic disorder of the nose that is caused by IgE-mediated inflammatory response following exposure to an allergen. The allergen could be in the form of dust, pollen, flower, animal dander, mold, cold or insect. Clinically, Allergic rhinitis occurs when there are recurrent nasal symptoms which are reversible either spontaneously or with medication in the preceding one year. Such symptoms include at least two of the following; excessive sneezing, running nose, nasal itching, nasal discharge, nasal congestion or obstruction.

Previous studies have linked Allergic Rhinitis (AR) to be co-existed with another form of allergic disorders including Allergic Conjunctivitis (AC), Atopic dermatitis and Allergic Asthma.

This study is aimed at assessing the feature of AR patients with coexistent AC as well as evaluating the effectiveness of the treatments offered to them.

Methodology:

This is cross-sectional descriptive study was conducted between August 2018 and November 2019 among 38 patients who presented to ENT and Ophthalmology departments of Federal Teaching Hospital Ido-Ekiti, Ekiti State, Southwestern Nigeria and were diagnosed with both

allergic rhinitis and allergic conjunctivitis.relevant data obtained were analyzed using SPSS version 20. $P \le 0.05$ was taken as significant.

Results:

The patients' age range between 8 and 81 years with a median age of 33 years. The majority were less than 45 years (63.2%) with the male to female ratio of almost. Eye pain, itching, and redness account for 97.4% of all the eye features, while the presence of cobblestones is the least and accounted for 5%. Nasal itching (92.1%) was the commonest nasal symptom.

Conclusion:

This research was conducted to correlate the features of allergic rhinitis with those of conjunctivitis and common management and preventive measures offered to the patients seen in our clinics.

Introduction

Allergic Rhinitis (AR) is a chronic, symptomatic allergic disorder of the nose that is caused by IgE-mediated inflammatory response following exposure to an allergen.¹ The allergen could be in form of dust, pollen, flower, animal dander, mold, cold or insect.² Clinically, Allergic rhinitis occurs when there are recurrent nasal symptoms which are reversible either spontaneously or with medication in the preceding one year.³ Such symptoms include at least two of the following; excessive sneezing, running nose, nasal itching, nasal discharge, nasal congestion or obstruction.³

The aim of this study was to determine the correlation between clinical features of Allergic Rhinitis (AR) with Allergic conjunctivitis (AC). The availability of such data will be necessary, not only for epidemiological purposes but also for clinical diagnosis and treatment of the affected individuals.

Methodology

This is cross-sectional descriptive study was conducted between August 2018 and November 2019 among 38 patients who presented to ENT and Ophthalmology departments of Federal

Teaching Hospital Ido-Ekiti, Ekiti State, Southwestern Nigeria and were diagnosed with both allergic rhinitis and allergic conjunctivitis. Relevant history was taken and clinical examinations were carried out on the patients. Adequate treatment was offered and each patient was followed up for 3 months to evaluate the response to the treatment given. The data collected from the patients were entered into the computer software and analyzed using SPSS version 20. $P \le 0.05$ was taken as significant.

Results

The patients' age range between 8 and 81 years with a median age of 33 years. The majority were less than 45 years (63.2%) with the male to female ratio of almost 1:1 (Figure 1). Eye pain, itching, and redness account for 97.4% of all the eye features(Table 1), while the presence of cobblestones is the least and accounted for 5%. Nasal itching (92.1%) was the commonest nasal symptom(Table 2) while the least nasal presentations were nasal polyp (18.4%) and sleep disturbance (28.9%). Only about one-tenth of the patients had allergen immunotherapy while all of them had antihistamine (Table 2). Sleep disturbance(Tables 4a & 4b) was found to be commoner among those with eye itching (29.7%), blurring of vision (31.8%) and those on a steroid (37.5%). All the patients(100%) benefitted from anti-histamine treatment(Table2), steroid in 28.9% and allergen immunotherapy treatment in 10.5%.

Discussion

Previous studies have linked Allergic Rhinitis (AR) to be co-existed with another form of allergic disorders including Allergic Conjunctivitis (AC), Atopic dermatitis and Allergic Asthma. 4,5,6

Allergic conjunctivitis (AC) is an acute or chronic inflammatory disorder of the conjunctiva and other ocular surfaces that are caused by IgE-mediated hypersensitivity reaction to an allergen.^{4,7}

The age of the patients seen in our study ranged between 8 and 81 years with a median age of 33 years. Most of them were less than 45 years (63.2%) while the male to female ratio was almost 1:1 (Figure 1). This showed that there was no gender predilection to allergic rhinitis nor allergic conjunctivitis.

The usual presentation of AC includes bilateral intense itching, lacrimation, redness, swollen eyelids, burning sensation with photophobia. These are similar to what was found in our patients. The eye features and the treatment offered to our patients are highlighted in Table 1. The most prevalent eye symptoms were pain, itching, and redness (97.4%) while coble stone was the least common presentation (13.2%) and about half of the patients were treated with VCT (52.6%). The commonest nasal symptom was nasal itching (92.1%) while the least presentations were nasal polyp (18.4%) and sleep disturbance (28.9%). Only about one-tenth of the patients had allergen immunotherapy while all of them had antihistamine (Table 2).

AC when co-existed with AR and allergic Asthma is referred to as Allergic Rhinoconjunctivitis.^{6,8} An allergic Rhinitis and allergic conjunctivitis disorder follow a pattern of seasonal and perennial forms, although, the pattern of nasal symptoms is mostly of perennial type with a peak incidence during the dry season while the pattern of ocular symptoms is mostly of seasonal type with a peak incidence during the rainy season.^{9,10}

Correlating the nasal and eye features of our patients revealed that Eye itching was found to be higher among those with nasal blockage, sleep disturbance, post nasal drip, and nasal polyp. This category of the patients from treatment with steroid, allergen immunotherapy as well as environmental control. Also, eye pain was observed to be more among those with nasal discharge, hawking, excoriation of external nares, post nasal drip, nasal polyp, steroid use, and

allergen immunotherapy. Similarly, eye redness was found to be higher among those with nasal discharge, hawking, excoriation of external nares, post nasal drip, nasal polyp, steroid use, and allergen immunotherapy. The proportion of patients with eye tearing was found to be higher among patients with nasal discharge, impaired activities of daily living, hawking and pale/ grey mucosa. As shown in the table, there was no significant association between the major eye symptoms and nasal features (Table 3a and 3b).

The cause of AR and AC and other forms of allergens is an interaction between genetic factors (Race, allergic predisposition, family history) and environmental factors (Allergens, air pollution, diet, water and exposure to cigarette smoke). AR and AC are diseases of childhood, adolescence and young adult irrespective of races, though, can occur at any age. Before puberty, more boys than girls are affected but after puberty, there is no gender bias. Before puberty,

In tables 4a and 4b, sleep disturbance was found to be commoner among those with eye itching (29.7%), blurring of vision (31.8%) and those on a steroid (37.5%). Also, a greater proportion of patients with the blurring of vision (90.9%) and hyperemia (88.9%) had sneezing while nasal itching was found to be higher among those with a blurring of vision, eye discharge, cobblestones, corneal abrasion and those on mast cell stabilizer as well as those on steroids. Furthermore, patients with eye redness, eye tearing, blurring of vision, eye discharge, eye pain hyperemia, and those on VCT were shown to have a higher prevalence of nasal discharge. Overall, major nasal symptoms were not found to be statistically associated with eye symptoms.

AR and AC and other forms of allergies have impacted heavy social and economic burdens on the general population, causing a reduction in the quality of life of the affected people, especially during the acute episode. ^{14, 15} According to a study by Olajide and colleagues from Ido-Ekiti,

commonly affected quality of life among children are irritability, absenteeism, sleep disruption and impaired social life. ¹⁵

The disorder of AR and AC are said to be common among the teenagers of high social economic class and those living in an industrial and urban area.¹⁷ AR has a close epidemiological relationship with AC and exhibits similar pathophysiological mechanism.⁶

These disorders are common in the population and many studies have observed the increasing prevalence of them in many countries.

The epidemiology of ocular allergy in an adult population was explored in the National Health and Nutritional Examination survey III.⁵ The survey found 6.4% reported ocular symptoms, 16.5% nasal symptoms and 29.7%both. ⁵ However, Michael R. Perkin et.al found the prevalence of AC as 17.5%, AR15.1%, and Rhino-conjunctivitis 13.4%⁴. Oladimeji S.M. and colleagues found the prevalence of AC as 26.0% and AR 40.6%⁹. In a study by Uche Okonkwo KC and colleagues, the Prevalence of Allergic rhinitis was 56.7% of which28.8% had allergic conjunctivitis. ¹ Generally, AC affects 5 – 22% of the general population. ¹⁶

Previous studies have demonstrated the increasing knowledge of the relationship between AR and AC. Clinical trials of intranasal therapies have proven efficacy in the treatment of AR and AC⁶. Majority of the respondents with AR also experienced symptoms of AC and other forms of allergies. Such clinical correlates include among others recurrent itching, redness of the eyes, persistent sneezing, runny nose with a positive fairly history of allergy. ¹⁷These correlate with the findings in our study (Table 4a &4b). However, none of these previous studies were available in this study area. This was the reason for our study.

Conclusion

This research was conducted to correlate the features of allergic rhinitis with those of conjunctivitis and common management and preventive measures offered to the patients.

References

- Uche-Okonkwo KC, Akinola MA, Jagun OOA, Oladeji SM, Johnson KJ. Allergic Rhinitis: Prevalence and associated factors among students of a secondary school in Southern Nigeria. Journal of Dental and Medical Sciences, 2016; 159(8): 117-120.
- 2. Abdulrahman H, Hadi U, Tarrat H, Gharagozlou M, kamel M, Soliman A et al. Nasal allergies in the Middle Eastern population. Results from the Allergies in Middle East survey.

 American Journal of Rhinology and Allergy2012;26(1):3-23
- 3. Desalu O, Salami A, Iseh K, Oluboyo P. Prevalence of self-reported Allergic Rhinitis and its Relationship with Asthma Among Adults in Nigerians. J Investig allergol Clin Immunol 2009. 19(6):474-480
- 4. Perkin MR, Bader T, Rudnicka AR, Strachan DP, Owen CG. Inter-Relationship between Rhinitis and Conjunctivitis in allergic Rhinoconjunctivitis and Associated Risk factors in Rural UK Children, PLOs 2015. Available at https://doi.org/10.1371/journal.pone.0143651. Accessed 5th November 2018.
- 5. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010; 126:778-783.

- 6. Bielory L. Allergic Conjunctivitis and the impact of Allergic Rhinitis. Current Allergy Asthma Reports 2010, 10(2): 122-134
- 7. Abah ER, Oladigbolu KK, Samaila E, Gani-Ikilama A. Ocular disorders in children in Zaria children's school. Niger J Clin Pract. 2011; 14:473-476.
- 8. Malu KN. Allergic conjunctivitis in Jos-Nigeria. Niger Med J.2014;166-170.
- 9. Oladeji SM, Nwawolo CC, Akinola OO. Prevalence of Allergic Disorder among University students in a tertiary Institution in Nigeria. Journal of Dental and Medical Sciences, 2015; 14(7): 12-16.
- 10. Oladeji SM, Nwawolo CC, Adewole O. Allergic rhinitis among adult bronchial asthmatic patients in Lagos, Nigeria. J West Afr Coll Surg 2013;3(2): 1-14
- 11. De Yun Wang. Risk factors of Allergic rhinitis: genetic or environmental? Their Clin risk Mang. 2005; 1(2): 115-123.
- 12. Adenuga OO. Samuel OJ. A pattern of eye diseases in an air force hospital in Nigeria. Park J. Ophthalmol. 2012; 28:144-148
- 13. Wade PD, Iwuora AN, Lopez L, Mohammed MA, Allergic conjunctivitis at sheikhayed regional eye care center, Gambia.
- 14. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011; 106:512-516.
- 15. Olajide GT, Adegbiji WA, Olubi O, Olajuyin AO, Aluko AA, Olatoke F. Otorhinolaryngological Manifestation of Allergy in South Western Nigerian Children. J.Allergy Ther 2018;9(3): 279.
- Katelaric C: Ocular Allergy pacific in the Asia Pacific region. Asia Pacific region. 2011;
 1:108-114.




Figure 1: Age and sex distribution of the patients

Table 1: Eye features and Treatment options offered

| | Yes | No |
|----------------------|-----------|-----------|
| Variable | n (%) | n (%) |
| Symptoms | | |
| Cobble stones | 5 (13.2) | 33 (86.8) |
| Blurring of vision | 22 (57.9) | 16 (42.1) |
| Eye tearing | 32 (84.2) | 6 (15.8) |
| Eye discharge | 35 (92.1) | 3 (7.9) |
| Hyperemia | 36 (94.7) | 2 (5.3) |
| Eye redness | 37 (97.4) | 1 (2.6) |
| Eye itching | 37 (97.4) | 1 (2.6) |
| Eye pain | 37 (97.4) | 1 (2.6) |
| Treatment | | |
| Mast cell stabilizer | 7 (18.4) | 31 (81.6) |
| Steroid | 8 (21.1) | 30 (78.9) |
| VCT | 20 (52.6) | 18 (47.4) |

 Table 2: Nasal Features and Treatment options offered

| | Yes | No |
|--------------------------------|------------|-----------|
| Variable | n (%) | n (%) |
| Symptoms | | |
| Nasal polyp | 7 (18.4) | 31 (81.6) |
| Sleep disturbance | 11 (28.9) | 27 (71.1) |
| Post nasal drip | 16 (42.1) | 22 (57.9) |
| Impairment of daily activities | 18 (47.4) | 20 (52.6) |
| Nasal blockage | 24 (63.2) | 14 (36.8) |
| Hawking | 29 (76.3) | 9 (23.7) |
| Excoriation of external nares | 31 (81.6) | 7 (18.4) |
| Pale mucosa / grey mucosa | 31 (81.6) | 7 (18.4) |
| Nasal discharge | 32 (84.7) | 6 (15.8) |
| Sneezing | 33 (86.8) | 5 (13.2) |
| Engorged inferior turbinate | 34 (89.5) | 4 (10.5) |
| Nasal itching | 35 (92.1) | 3 (7.9) |
| Treatment | | |
| Allergen immunotherapy | 4 (10.5) | 34 (89.5) |
| Environmental control | 8 (21.1) | 30 (78.9) |
| Steroid | 11 (28.9) | 27 (71.1) |
| Anti-histamine | 38 (100.0) | 0 (0.0) |

Table 3A: Correlating Major Eye symptoms with the nasal features

| Variable | Eye Itching | | | Eye Pain | | | | Eye Tea | | |
|-----------------------|-------------|---------|---------|------------|----------|---------|------------|----------|---------|----------|
| | Yes | No | p value | Yes | No | p value | Yes | No | p value | Yes |
| | n (%) | n (%) | | n (%) | n (%) | | n (%) | n (%) | | n (%) |
| Sneezing | | | | | | | | | | |
| Yes | 32 (97.0) | 1 (3.0) | 0.269 | 32 (97.0) | 1 (3.0) | 0.269 | 32 (97.0) | 1 (3.0) | 0.269 | 27 (81.8 |
| No | 5 (100.0) | 0 (0.0) | | 5 (100.0) | 0 (0.0) | | 5 (100.0) | 0 (0.0) | | 5 (100.0 |
| Nasal Discharge | | | | | | | | | | |
| Yes | 31 (96.9) | 1 (3.1) | 0.341 | 32 (100.0) | 0 (0.0) | 0.341 | 32 (100.0) | 0 (0.0) | 0.341 | 27 (84.4 |
| No | 6 (100.0) | 0 (0.0) | | 5 (83.3) | 1 (16.7) | | 5 (83.3) | 1 (16.7) | | 5 (83.3) |
| Nasal Itching | | | | | | | | | | |
| Yes | 34 (97.1) | 1 (2.9) | 0.113 | 34 (97.1) | 1 (2.9) | 0.113 | 34 (97.1) | 1 (2.9) | 0.113 | 29 (82.9 |
| No | 3 (100.0) | 0 (0.0) | | 3 (100.0) | 0 (0.0) | | 3 (100.0) | 0 (0.0) | | 3 (100.0 |
| Nasal Blockage | | | | | | A 4 | | | | |
| Yes | 24 (100.0) | 0 (0.0) | 0.782 | 23 (95.8) | 1 (4.2) | 0.782 | 23 (95.8) | 1 (4.2) | 0.782 | 20 (83.3 |
| No | 13 (92.9) | 1 (7.1) | | 14 (100.0) | 0 (0.0) | # 4 | 14 (100.0) | 0 (0.0) | | 12 (85.7 |
| Sleep Disturbance | | | | | | | | | | |
| Yes | 11 (100.0) | 0 (0.0) | 0.638 | 10 (90.9) | 1 (9.1) | 0.638 | 10 (90.9) | 1 (9.1) | 0.638 | 9 (81.8) |
| No | 26 (96.3) | 1 (3.7) | | 27 (100.0) | 0 (0.0) | | 27 (100.0) | 0 (0.0) | | 23 (85.2 |
| Impairment of Daily | | | | | | | | | | |
| Activities | | | | | | | | | | |
| Yes | 17 (94.4) | 1 (5.6) | 0.956 | 17 (94.4) | 1 (5.6) | 0.956 | 17 (94.4) | 1 (5.6) | 0.956 | 16 (88.9 |
| No | 20 (100.0) | 0 (0.0) | | 20 (100.0) | 0 (0.0) | | 20 (100.0) | 0 (0.0) | | 16 (80.0 |
| Hawking | | | | | 4 | | | | | |
| Yes | 28 (96.6) | 1 (3.4) | 0.530 | 29 (100.0) | 0 (0.0) | 0.530 | 29 (100.0) | 0 (0.0) | 0.530 | 25 (86.2 |
| No | 9 (100.0) | 0 (0.0) | | 8 (88.9) | 1 (11.1) | | 8 (88.9) | 1 (11.1) | | 7 (77.8) |
| Excoriation of | | - | | | | | | | | |
| External Nares | | | | | | | | | | |
| Yes | 30 (96.8) | 1 (3.2) | 0.408 | 31 (100.0) | 0 (0.0) | 0.408 | 31 (100.0) | 0 (0.0) | 0.408 | 25 (80.6 |
| No | 7 (100.0) | 0 (0.0) | | 6 (85.7) | 1 (14.3) | | 6 (85.7) | 1 (14.3) | | 7 (100.0 |
| | | - | Es. | • | | | | | | - |

Table 3B: Correlating Major Eye symptoms with the nasal features

| | Eye Itching | | | Eye pain | | | Eye redn | ess | | Eye tearing | | |
|------------|-------------|----------|-----------------------|----------|-------|-----------------------|----------|-------|-----------------------|-------------|-------|-----------------------|
| | Yes | No | <i>p</i> valu e | Yes | No | <i>p</i> valu e | Yes | No | <i>p</i> valu e | Yes | No | <i>p</i> valu e |
| Variable | n (%) | n (%) | | n (%) | n (%) | • | n (%) | n (%) | • | n (%) | n (%) | C |
| Pale/ Grey | | | | | | | | | | | | |
| Mucosa | | | | | | | | | | | | |
| Yes | 30(96.8 | 1(3. | 0.40 | 30(96.8 | 1(3.2 | 0.40 | 30(96.8 | 1(3.2 | 0.40 | 27(87. | 4(12. | 0.65 |

| - | | | | | | | | | | | | |
|-------------|----------|------------|------|--------------|------------|-----------|--------------|------------|-----------|--------------|-------------|-----------|
| |) | 2) | 8 |) |) | 8 |) |) | 8 | 1) | 9) | 0 |
| No | 7(100.0 | 0(0. | | 7(100.0 | 0(0.0 | | 7(100.0 | 0(0.0 | | 5(71.4 | 2(28. | |
| |) | 0) | |) |) | |) |) | |) | 6) | |
| Engorged | | | | | | | | | | | | |
| Inferior | | | | | | | | | | | | |
| Turbinate | 33(97.1 | 1(2. | 0.19 | 33(97.1 | 1(2.9 | 0.19 | 33(97.1 | 1(2.9 | 0.19 | 28(82. | 6(17. | 0.84 |
| Yes | 33(37.1 | 9) | 2 | 33(37.1 | 1(2.5 | 2 | 33(37.1 | 1(2.5 | 2 | 20(02. 4) | 6) | 9 |
| No | 4(100.0 | 0(0. | 2 | 4(100.0 | 0(0.0 | 2 | 4(100.0 | 0(0.0 | 2 | 4(100. | 0(0.0 | , |
| 110 | 1 | 0) | |) |) | |) |) | | 0) |) | |
| Post Nasal | , | ٥, | | , | , | | , | , | | 0, | , | |
| drip | | | | | | | | | | A | | |
| Yes | 16(100. | 0(0. | 0.87 | 16(100. | 0(0.0 | 0.87 | 16(100. | 0(0.0 | 0.87 | 13(81. | 3(18. | 0.97 |
| | 0) | 0) | 1 | 0) |) | 1 | 0) |) | 1 | 3) | 8) | 4 |
| No | 21(95.5 | 1(4. | | 21(95.5 | 1(4.5 | | 21(95.5 | 1(4.5 | | 19(86. | 3(13. | |
| |) | 5) | |) |) | |) |) | 1 | 4) | 6) | |
| Nasal Polyp | | | | | | | | . 1 | | | | _ |
| Yes | 7(100.0 | 0(0. | 0.40 | 7(100.0 | 0.0)0 | 0.40 | 7(100.0 | 0(0.0 | 0.40 | 5(71.4 | 2(28. | 0.65 |
| |) | 0) | 8 |) |) | 8 |) |) | 8 |) | 6) | 0 |
| No | 30(96.8 | 1(3. | | 30(96.8 | 1(3.2 | | 30(96.8 | 1(3.2 | | 27(87. | 4(12. | |
| Anti- |) | 2) | |) |) | 4 | 7 | | > | 1) | 9) | |
| histamine | | | | | | | | | | | | |
| Yes | 37(97.4 | 1(2. | | 37(97.4 | 1(2.6 | | 37(97.4 | 1(2.6 | | 32(84. | 6(15. | |
| |) | 6) | |) | 4) | |) |) | | 2) | 8) | |
| Steroid | , | -, | | , | ∢′. | | | , | | -, | -, | |
| Yes | 11(100. | 0(0. | 0.63 | 11(100. | 0(0.0 | 0.63 | 11(100. | 0(0.0 | 0.63 | 7(63.6 | 4(36. | 0.08 |
| | 0) | 0) | 8 | 0) |) | 8 | 0) |) | 8 |) | 4) | 3 |
| No | 26(96.3 | 1(3. | | 26(96.3 | 1(3.7 | | 26(96.3 | 1(3.7 | | 25(92. | 2(7.4 | |
| |) | 7) | |) | 1 | |) |) | | 6) |) | |
| Allergen | | | | | | | | | | | | |
| Immunother | | | | A | | | | | | | | |
| ару | 4/4.00.0 | 2/0 | 0.10 | 4/4.00.0 | 0/0.0 | 0.40 | 4/400.0 | 0/0.0 | 0.40 | 2/50.0 | 2/50 | 0.20 |
| Yes | 4(100.0 | 0(0. | 0.19 | 4(100.0 | 0.0)0 | 0.19 2 | 4(100.0 | 0.0)0 | 0.19 2 | 2(50.0 | 2(50. | 0.20 8 |
| No | 33(97.1 | 0) 1(2. | 2 |) 33(97.1 |) 1(2.9 | 2 |) 33(97.1 |) 1(2.9 | 2 |) 30(88. | 0) 4(11. | ٥ |
| INO | 33(37.1 | 9) | |) | 1(2.5 | | 33(37.1 | 1(2.5 | | 2) | 4(11. 8) | |
| Environment | A , A | 3) | | , | , | | , | , | | 2) | O, | |
| al Control | A 4 | | | | | | | | | | | |
| Yes | 8(100.0 | 0(0. | 0.47 | 7(87.5) | 1(12. | 0.47 | 7(87.5) | 1(12. | 0.47 | 5(62.5 | 3(37. | 0.17 |
| | |) (o) | 1 | , , | 5) | 1 | , , | ` 5) | 1 | `) | ` 5) | 7 |
| No | 29(96.7 | 1(3. | | 30(100. | 0.0)0 | | 30(100. | 0(0.0 | | 27(90. | 3(10. | |
| |) | 3) | | 0) |) | | 0) |) | | 0) | 0) | |
| Asthma | | | | | | | | | | | | |
| Yes | 9(100.0 | 0(0. | 0.53 | 8(88.9) | 1(11. | 0.53 | 8(88.9) | 1(11. | 0.53 | 6(66.7 | 3(33. | 0.25 |
| |) | 0) | 0 | | 1) | 0 | | 1) | 0 |) | 3) | 8 |
| No | 28(96.6 | 1(3. | | 29(100. | 0.0)0 | | 29(100. | 0.0)0 | | 26(89. | 3(10. | |
| |) | 4) | | 0) |) | | 0) |) | | 7) | 3) | |

Table 4A: Correlating Major Nasal symptoms with the Eye Symptoms

| | Sleep disturbance | | | Sneezi | ng | | Nasal i | tching | | Nasal discharge | | |
|--------------------|-------------------|--------------|-----------|--------------|-------------|------------------|--------------|------------|------------------|-----------------|-------|------------------|
| | Yes | No | p valu | Yes | No | <i>p</i> valu | Yes | No | <i>p</i> valu | Yes | No | <i>p</i> valu |
| Variable | n (%) | n (%) | е | n (%) | n (%) | е | n (%) | n (%) | e | n (%) | n (%) | е |
| Eye redness | | | | | | | | | | | 1 4 | |
| Yes | 10(27. | 27(73 | 0.63 | 32(86 | 5(13 | 0.26 | 34(91 | 3(8. | 0.11 | 32(86 | 5(13. | 0.34 |
| | 0) | .0) | 8 | .5) | .5) | 9 | .9) | 1) | 4 | .5) | 5) | 2 |
| No | 1(100. | 0(0.0 | | 1(100 | 0(0. | | 1(100 | 0(0. | | 0(0.0 | 1(100 | |
| | 0) |) | | .0) | 0) | | .0) | 0) | A . |) | .0) | |
| Eye itching | · | ŕ | | · | • | | | | A) | · | · | |
| Yes | 11(29. | 26(70 | 0.63 | 32(86 | 5(13 | 0.26 | 34(91 | 3(8. | 0.11 | 31(83 | 6(16. | 0.34 |
| | 7) | .3) | 8 | .5) | .5) | 9 | .9) | 1) | 4 | .8) | 2) | 1 |
| No | 0(0.0) | 1(100 | | 1(100 | 0(0. | | 1(100 | 0(0. | | 1(100 | 0(0.0 | |
| | ` , | .0) | | .0) | 0) | | .0) | 0) | | .0) | `) | |
| Eye tearing | | , | | | , | | , | , | | , | , | |
| Yes | 9(28.1 | 23(71 | 0.81 | 27(84 | 5(15 | 0.70 | 29(90 | 3(9. | 0.96 | 27(84 | 5(15. | 0.58 |
| |) | .9) | 6 | .4) | .6) | 3 | .6) | 4) | 4 | .4) | 6) | 5 |
| No | 2(33.3 | 4(66. | | 6(100 | 0(0. | | 6(100 | 0(0. | | 5(83. | 1(16. | _ |
| |) | 7) | 4 | .0) | 0) | | .0) | 0) | | 3) | 7) | |
| Blurring of vision | , | ., | 1 | ,,, | | | , | ٠, | | ٥, | -, | |
| Yes | 7(31.8 | 15(68 | 0.92 | 20(90 | 2(9. | 0.70 | 21(95 | 1(4. | | 19(86 | 3(13. | 0.97 |
| |) | .2) | 4 | .9) | 1) | 1 | .5) | 5) | | .4) | 6) | 5 |
| No | 4(25.0 | 12(75 | | 13(81 | 3(18 | _ | 14(87 | 2(12 | 0.77 | 13(81 | 3(18. | _ |
| | 1,25.0 | .0) | | .3) | .8) | | .5) | .5) | 3 | .3) | 8) | |
| Eye pain | * | | | , | .0, | | , | , | | , | ٥, | |
| Yes | 10(27. | 27(73 | 0.63 | 32(86 | 5(13 | 0.26 | 34(91 | 3(8. | | 32(86 | 5(13. | 0.34 |
| .63 | 0) | .0) | 8 | .5) | .5) | 9 | .9) | 1) | | .5) | 5) | 2 |
| No | 1(100. | 0(0.0 | Ü | 1(100 | 0(0. | 3 | 1(100 | 0(0. | 0.11 | 0(0.0 | 1(100 | _ |
| 110 | 0) |) | | .0) | 0(0. | | .0) | 0(0. | 4 |) | .0) | |
| Eye discharge | 0) | , | | .0) | U) | | .0, | U) | 7 | , | .0) | |
| Yes | 10(28. | 25(71 | 0.62 | 30(85 | 5(14 | 0.85 | 33(94 | 2(5. | | 30(85 | 5(14. | 0.96 |
| 103 | 6) | .4) | 5 | .7) | .3) | 2 | .3) | 2(3. 7) | | .7) | 3) | 4 |
| No | 1(33.3 | .4) 2(66. | J | ./) 3(100 | .s) 0(0. | ۷ | .s) 2(66. | 1(33 | 0.55 | .7) 2(66. | 1(33. | 4 |
| INU | | | | • | | | | .3) | 0.55 7 | • | | |
| Hunorom: |) | 7) | | .0) | 0) | | 7) | .3) | / | 7) | 3) | |
| Hyperemia | 10/27 | 26/72 | 0.00 | 22/00 | 1/11 | 0.64 | 22/04 | 2/0 | | 21/06 | F/43 | 0.74 |
| Yes | 10(27. | 26(72 | 0.89 | 32(88 | 4(11 | 0.61 | 33(91 | 3(8. | | 31(86 | 5(13. | 0.71 |
| | 8) | .2) | 9 | .9) | .1) | 1 | .7) | 3) | | .1) | 9) | 3 |
| No | 1(50.0 | 1(50. | | 1(50. | 1(50 | | 2(100 | 0(0. | 0.35 | 1(50. | 1(50. | |

) 0) 0) .0) .0) 7 0) 0)

Table 4B: Correlating Major Nasal symptoms with the Eye Symptoms

| | Sleep disturbance Sneezing | | | ng | Nasal itching | | | | Nasal discharge | | | |
|-----------------|----------------------------|-------|------|-------|---------------|------|----------|----------|-----------------|-------|-------|------|
| | Yes | No | р | Yes | No | p | Yes | No | p | Yes | No | p |
| | | | valu | | | valu | | ₽ | valu | | | valu |
| | | | е | | | e | | | е | | | е |
| Variable | n (%) | n (%) | | n (%) | n | | n (%) | n | | n (%) | n (%) | |
| | | | | | (%) | | 1 | (%) | | | | |
| Cobbles stones | | | | | | | b | | | | | |
| Yes | 0(0.0) | 5(100 | 0.31 | 4(80. | 1(20 | 0.82 | 5(100 | 0(0. | 0.85 | 4(80. | 1(20. | 0.70 |
| | | .0) | 6 | 0) | .0) | 3 | .0) | 0) | 2 | 0) | 0) | 3 |
| No | 11(33. | 22(66 | A | 29(87 | 4(12 | | 30(90 | 3(9. | | 28(84 | 5(15. | |
| | 3) | .7) | | .9) | .1) | | .9) | 1) | | .8) | 2) | |
| Cornea abrasion | | | | | | | | | | | | |
| Yes | 1(20.0 | 4(80. | 0.95 | 4(80. | 1(20 | 0.82 | 5(100 | 0(0. | 0.85 | 4(80. | 1(20. | 0.70 |
| | 1 | 0) | 6 | 0) | .0) | 3 | .0) | 0) | 2 | 0) | 0) | 3 |
| No | 10(30. | 23(69 | | 29(87 | 4(12 | | 30(90 | 3(9. | | 28(84 | 5(15. | |
| | 3) | .7) | | .9) | .1) | | .9) | 1) | | .8) | 2) | |
| VCT | | | | | | | | | | | | |
| Yes | 5(25.0 | 15(75 | 0.57 | 17(85 | 3(15 | 0.89 | 18(90 | 2(10 | 0.92 | 17(85 | 3(15. | 0.76 |
| |) | .0) | 2 | .0) | .0) | 9 | .0) | .0) | 4 | .0) | 0) | 0 |
| No | 6(33.3 | 12(66 | | 16(88 | 2(11 | | 17(94 | 1(5. | | 15(83 | 3(16. | |
| |) | .7) | | .9) | .1) | | .4) | 6) | | .3) | 7) | |
| Mast cell | | | | | | | | | | | | |
| stabilizer | | | | | | | | | | | | |
| Yes | 1(14.3 | 6(85. | 0.62 | 6(85. | 1(14 | 0.60 | 7(100 | 0(0. | 0.93 | 5(71. | 2(28. | 0.6 |
| | | | | | | | | | | | | |

| |) | 7) | 7 | 7) | .3) | 2 | .0) | 0) | 3 | 4) | 6) | 1 |
|---------|--------|-------|------|-------|------|------|-------|------|------|-------|-------|------|
| No | 10(32. | 21(67 | | 27(87 | 4(12 | | 28(90 | 3(9. | | 27(87 | 4(12. | |
| | 3) | .7) | | .1) | .9) | | .3) | 7) | | .1) | 9) | |
| Steroid | | | | | | | | | | | | |
| Yes | 3(37.5 | 5(62. | 0.87 | 6(75. | 2(25 | 0.59 | 8(100 | 0(0. | 0.84 | 6(75. | 2(25. | 0.79 |
| |) | 5) | 2 | 0) | .0) | 9 | .0) | 0) | 5 | 0) | 0) | 6 |
| No | 8(26.7 | 22(73 | | 27(90 | 3(10 | | 27(90 | 3(10 | | 26(86 | 4(13. | |
| |) | .3) | | .0) | .0) | | .0) | .0) | | .7) | 3) | |